Literature DB >> 19648302

Purified protein derivative response in juvenile idiopathic arthritis.

Evrim Kiray1, Ozgur Kasapcopur, Vedat Bas, Ayla Kamburoglu-Goksel, Kenan Midilli, Nil Arisoy, Yucel Tastan.   

Abstract

OBJECTIVE: To examine the purified protein derivative (PPD) response that develops depending upon Th1 immune response in children with juvenile idiopathic arthritis (JIA).
METHODS: PPD skin test was performed in 115 children with JIA who were vaccinated with bacillus Calmette-Guerin (BCG), and then they were compared to the PPD response of 45 healthy children of the same age who were vaccinated with BCG. Children with a PPD induration > or = 5 mm were accepted as PPD-positive. PPD induration > or = 10 mm was accepted as a limit for suspecting tuberculosis.
RESULTS: PPD induration size and PPD positivity rates (PPD > or = 5 mm) of children with JIA were significantly lower than those of healthy children. The mean of PPD induration size was significantly lower (p < 0.0001) in patients with either 1 BCG vaccine (3.7 +/- 3.6) or more than 1 BCG vaccine than controls with either 1 BCG vaccine (7.10 +/- 3.2) or more than 1 BCG vaccine (10.05 +/- 4.1). PPD was positive in 35.9% of patients with JIA vaccinated once (n = 32), in 50% of patients with JIA vaccinated more than once (n = 13), in 82.1% of controls vaccinated once (n = 23), and in 88.2% of controls vaccinated more than once. This result was statistically significant (patients, p = 0.03; controls, p = 0.039). It was determined that neither the activity of the disease nor the use of corticosteroid and methotrexate affected the PPD response.
CONCLUSION: The response to PPD, which is one of the Th1 cell-type responses, was significantly lower in BCG-vaccinated children with JIA compared to healthy children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19648302     DOI: 10.3899/jrheum.090173

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Treatment in juvenile rheumatoid arthritis and new treatment options.

Authors:  Özgür Kasapçopur; Kenan Barut
Journal:  Turk Pediatri Ars       Date:  2015-03-01

Review 2.  Vaccinations in juvenile chronic inflammatory diseases: an update.

Authors:  Clovis A Silva; Nadia E Aikawa; Eloisa Bonfa
Journal:  Nat Rev Rheumatol       Date:  2013-07-02       Impact factor: 20.543

3.  Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Authors:  Omer Kilic; Ozgur Kasapcopur; Yildiz Camcioglu; Haluk Cokugras; Nil Arisoy; Necla Akcakaya
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

4.  Screening for Latent Tuberculosis in Children With Immune-mediated Inflammatory Diseases Treated With Anti-tumor Necrosis Factor Therapy: Comparison of Tuberculin Skin and T-SPOT Tuberculosis Tests.

Authors:  Saniye Gİrİt; Ayşe Ayzit Atabek; Ebru Şenol; Tuba KoÇkar Kizilirmak; Sevgi Pekcan; Şafak GÖktaŞ; Sedat Öktem; Özgür KasapÇopur; Haluk ÇokuĞraŞ
Journal:  Arch Rheumatol       Date:  2019-06-25       Impact factor: 1.472

Review 5.  Vaccinations in paediatric rheumatology: an update on current developments.

Authors:  Noortje Groot; Marloes W Heijstek; Nico M Wulffraat
Journal:  Curr Rheumatol Rep       Date:  2015-07       Impact factor: 4.592

Review 6.  What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?

Authors:  Joost F Swart; Sytze de Roock; Nico M Wulffraat
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

Review 7.  Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.

Authors:  Giovanna Ferrara; Greta Mastrangelo; Patrizia Barone; Francesco La Torre; Silvana Martino; Giovanni Pappagallo; Angelo Ravelli; Andrea Taddio; Francesco Zulian; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2018-07-11       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.